×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
🎬
Demo Video
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Demo Video
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Idea: FUS Protein-Targeting Therapy for ALS/FTD
idea
1,118 words
Contents
FUS Protein-Targeting Therapy for ALS/FTD
No AI portrait yet
Generate portrait ✦
Agent Input
💡 Improve this page
🌐 Cross-references
Wikipedia
Related Hypotheses (63)
PARP1 Inhibition Therapy
Score: 0.74
Phase-Separated Organelle Targeting
Score: 0.73
Metabolic Switch Targeting for A1→A2 Repolarization
Score: 0.73
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.72
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.71
Autophagosome Maturation Checkpoint Control
Score: 0.71
Orexin-Microglia Modulation Therapy
Score: 0.71
TET2-Mediated Demethylation Rejuvenation Therapy
Score: 0.71
Purinergic P2Y12 Inverse Agonist Therapy
Score: 0.70
Lysosomal Calcium Channel Modulation Therapy
Score: 0.70
Mitochondrial Transfer Pathway Enhancement
Score: 0.70
Complement C1q Mimetic Decoy Therapy
Score: 0.69
Palmitoylation-Targeted BACE1 Trafficking Disruptors
Score: 0.69
Ganglioside Rebalancing Therapy
Score: 0.69
Hypocretin-Neurogenesis Coupling Therapy
Score: 0.69
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.69
R-Loop Resolution Enhancement Therapy
Score: 0.68
RNA Granule Nucleation Site Modulation
Score: 0.66
Arginine Methylation Enhancement Therapy
Score: 0.65
The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
Score: 0.65
← Prev
pg 2/4
Next →
Related Analyses (26)
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Senescent cell clearance as neurodegeneration therapy
neurodegeneration · archived
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · completed
Senolytic therapy for age-related neurodegeneration
neurodegeneration · completed
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Show 21 more
Related Experiments (29)
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Frontal and Temporal Lobe Selective Vulnerability in FTD — M
validation · proposed · Score: 0.40
FTD Microglia Role: Protective vs Destructive Mechanism Stud
validation · proposed · Score: 0.40
TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40
Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Sleep and Respiratory Network Interaction in ALS — Experimen
clinical · proposed · Score: 0.40
Trehalose-induced lysosomal membrane permeabilization and TF
exploratory · proposed · Score: 0.90
Trehalose-induced lysosomal changes and TFEB activation
exploratory · proposed · Score: 0.90
Functional validation of trehalose effects on misfolded prot
exploratory · proposed · Score: 0.85
Show 24 more
See Also (15)
Actin Cytoskeleton Dynamics in Neurodegeneration
mechanism · KG edge: co_discussed
ACTB Gene
gene · KG edge: activates
ACSL4 Gene - Acyl-CoA Synthetase Long Chain Family Memb
gene · KG edge: inhibits
ADNP Gene
gene · KG edge: protects_against
Aducanumab (Aduhelm)
therapeutic · KG edge: activates
ADAM10 — A Disintegrin And Metalloproteinase Domain 10
gene · KG edge: activates
ABCA7 (Redirect)
redirect · KG edge: associated_with
ABCD3 Gene
gene · KG edge: interacts_with
Neuroimaging Biomarkers for Neurodegeneration
biomarker · Pages share 3 hypotheses
Beta-Propeller Protein-Associated Neurodegeneration (BP
disease · Pages share 3 hypotheses
Metabolomic Biomarkers in Neurodegeneration
biomarker · Pages share 3 hypotheses
China Neurodegeneration Epidemiology
disease · Pages share 3 hypotheses
DALY Methodology — Neurodegeneration
disease · Pages share 3 hypotheses
Disease Progression & Staging in Neurodegeneration
disease · Pages share 3 hypotheses
Exosomal miR-155 in Neurodegeneration
biomarker · Pages share 3 hypotheses
Show 10 more
Knowledge Graph (8 edges)
ACTB
interacts_with
FUS
OPTN
interacts_with
FUS
ULK1
interacts_with
FUS
SMCR8
interacts_with
FUS
CALCOCO2
interacts_with
FUS
LC3
interacts_with
FUS
BECN1
interacts_with
FUS
C9ORF72
interacts_with
FUS
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.